Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 54-62 , February 2010

Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer

  • C.J.H. van de Velde

      Affiliations

    • Leiden University Medical Center, Department of Surgery, P.O. Box 9600, 2300 RC, Leiden, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 71 526 2309; fax: +31 71 526 6750.
    • ,
  • S. Verma

      Affiliations

    • Sunnybrook Odette Cancer Center and Sunnybrook Health Sciences Center, University of Toronto, 2075 Bayview Avenue, Room T2 045, Toronto, Ontario, Canada M4N 3M5
    • Tel.: +1 416 480 5248; fax: +1 416 480 6002.
    • ,
  • J.G.H. van Nes

      Affiliations

    • Leiden University Medical Center, Department of Surgery, P.O. Box 9600, 2300 RC, Leiden, The Netherlands
    • Tel.: +31 71 526 2309; fax: +31 71 526 6744.
    • ,
  • C. Masterman

      Affiliations

    • ACUMED, KnowledgePoint360 Group, 2nd Floor, 6 New Bridge Street, London EC4V 6AB, United Kingdom
    • Tel.: +44 20 7842 0883; fax: +44 20 7353 0623.
    • ,
  • K.I. Pritchard

      Affiliations

    • Sunnybrook Odette Cancer Center and Sunnybrook Health Sciences Center, University of Toronto, 2075 Bayview Avenue, Room T2 045, Toronto, Ontario, Canada M4N 3M5
    • Tel.: +1 416 480 4616; fax: +1 416 480 6002.

Received 30 September 2009 ,Accepted 13 October 2009.

References 

  1. Early breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–1144
  3. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92:2247–2258
  4. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101–2109
  5. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:4883–4890
  6. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol. 2007;25:486–492
  7. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–570
  8. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53
  9. Berstein LM, Zheng H, Yue W, et al. New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer. 2003;10:267–277
  10. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852–856
  11. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl Cancer Inst. 1994;86:1534–1539
  12. Elisaf M, Bairaktari E, Nicolaides C, et al. The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res. 1996;16:2725–2728
  13. Early breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467
  14. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer. US Oncol Dis. 2007;1:18
  15. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092
  16. Coombes C, Kilburn L, Beare S, et al. Survival and safety post study treatment completion: an updated analysis of the Intergroup Exemestane Study (IES). Eur J Cancer Suppl. 2009;7:263;(abstract 5.010; oral)
  17. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23:5138–5147
  18. Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol. 2006;17(Suppl. 7):vii10–vii14
  19. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007;25:2664–2670
  20. Jakesz R, Gnant M, Griel R et al. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. In: Oral presentation at San Antonio breast cancer symposium (SABCS), 10–14 December, San Antonio, Texas, USA; 2008.
  21. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–462
  22. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006;7:991–996
  23. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  24. Jones SE, Seynaeve C, Hasenburg A et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. In: Oral presentation at San Antonio breast cancer symposium (SABCS), 10–14 December, San Antonio, Texas, USA; 2008.
  25. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  26. BIG 1–98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361(8):766–76.
  27. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684–690
  28. Wilking N, Isaksson E, Schoultz EV. Tamoxifen and secondary tumours. An update. Drug Saf. 1997;16:104–117
  29. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8:119–127
  30. Hadji P, Ziller M, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised sub-study. Ann Oncol. 2009;20:203–207
  31. van Nes JGH, Papapoulos SE, Braun JJ et al. Effect of exemestane on bone turnover markers and bone mineral density (BMD): 2 year results of the Dutch/Belgian Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. In: Poster presentation at San Antonio breast cancer symposium (SABCS), 10–14 December, San Antonio, Texas, USA; 2008.
  32. Coleman RE, Banks LM, Girgis SI et al. Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study. In: Poster presentation at San Antonio breast cancer symposium (SABCS), 10–14 December, San Antonio, Texas, USA; 2008.
  33. Markopoulos C, Polychronis A, Dafni U, Koukouras D, Zobolas V, Tzorakoleftherakis E. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Ann Oncol. 2009;20:49–55
  34. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006;24:910–917
  35. van Nes JGH, Voskuil DW, van Leeuwen FE et al. Quality of life in relation to hormonal treatment of postmenopausal women in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. In: Oral presentation at San Antonio breast cancer symposium (SABCS), 10–14 December, San Antonio, Texas, USA; 2008.
  36. Schilder CM, Seynaeve C, Linn SC et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: results from the TEAM trial neuropsychological study. J Clin Oncol 2008, accepted for publication.
  37. In:  Sabate E editors. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003;
  38. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99:215–220
  39. Owusu C, Busit D, Field T, Lash TL, Thwin S, Silliman R. Tamoxifen discontinuance among women aged 65 years and older with estrogen receptor positive breast cancer (abstract). J Clin Oncol. 2008;24(18S):39s
  40. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, snis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556–562
  41. Available from: www.ClinicalTrials.gov.
  42. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005;23:7512–7517
  43. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008;26:1059–1065
  44. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol. 2007;25:3846–3852
  45. Bartlett JMS, Brookes CL, Billingham LJ et al. A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen. In: Oral presentation at San Antonio breast cancer symposium (SABCS, 10–14 December), San Antonio, Texas, USA; 2008.
  46. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113–121
  47. Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol. 2006;24:3708–3709
  48. Goetz M, Ames M, Gnant M et al. Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. In: Oral presentation at San Antonio breast cancer symposium (SABCS), 10–14 December, San Antonio, Texas, USA; 2008.
  49. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619–629
  50. National Comprehensive Cancer Network. NCCN clinical practical guidelines in oncology: breast cancer. V.2.2008. Available from: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.

PII: S0305-7372(09)00156-X

doi: 10.1016/j.ctrv.2009.10.003

Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 54-62 , February 2010

Article Tools